SLP vs. DOCS, WIX, YOU, CNIC, SRAD, NET, GVP, ARBB, CYN, and INSE
Should you be buying Sylvania Platinum stock or one of its competitors? The main competitors of Sylvania Platinum include Dr. Martens (DOCS), Wickes Group (WIX), YouGov (YOU), CentralNic Group (CNIC), Stelrad Group (SRAD), Netcall (NET), Gabelli Value Plus+ Trust (GVP), Arbuthnot Banking Group (ARBB), CQS Natural Resources Growth and Income (CYN), and Inspired (INSE). These companies are all part of the "computer software" industry.
Sylvania Platinum vs. Its Competitors
Dr. Martens (LON:DOCS) and Sylvania Platinum (LON:SLP) are both small-cap computer software companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.
In the previous week, Sylvania Platinum had 2 more articles in the media than Dr. Martens. MarketBeat recorded 3 mentions for Sylvania Platinum and 1 mentions for Dr. Martens. Dr. Martens' average media sentiment score of 0.00 beat Sylvania Platinum's score of -0.36 indicating that Dr. Martens is being referred to more favorably in the media.
Sylvania Platinum has a net margin of 8.55% compared to Dr. Martens' net margin of 7.89%. Dr. Martens' return on equity of 18.91% beat Sylvania Platinum's return on equity.
Dr. Martens currently has a consensus target price of GBX 6,000, suggesting a potential upside of 7,702.34%. Sylvania Platinum has a consensus target price of GBX 93, suggesting a potential upside of 32.86%. Given Dr. Martens' higher possible upside, equities analysts plainly believe Dr. Martens is more favorable than Sylvania Platinum.
69.5% of Dr. Martens shares are owned by institutional investors. Comparatively, 17.8% of Sylvania Platinum shares are owned by institutional investors. 4.4% of Dr. Martens shares are owned by company insiders. Comparatively, 12.2% of Sylvania Platinum shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 3.9%. Sylvania Platinum pays an annual dividend of GBX 2 per share and has a dividend yield of 2.9%. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Sylvania Platinum pays out 93.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Martens is clearly the better dividend stock, given its higher yield and lower payout ratio.
Dr. Martens has higher revenue and earnings than Sylvania Platinum. Dr. Martens is trading at a lower price-to-earnings ratio than Sylvania Platinum, indicating that it is currently the more affordable of the two stocks.
Dr. Martens has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Sylvania Platinum has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.
Summary
Dr. Martens beats Sylvania Platinum on 10 of the 18 factors compared between the two stocks.
Get Sylvania Platinum News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sylvania Platinum Competitors List
Related Companies and Tools
This page (LON:SLP) was last updated on 7/6/2025 by MarketBeat.com Staff
